Literature DB >> 18223692

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.

M Asim1, I A Siddiqui, B B Hafeez, A Baniahmad, H Mukhtar.   

Abstract

Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223692     DOI: 10.1038/sj.onc.1211016

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

Review 1.  Metabolic Dysregulation Controls Endocrine Therapy-Resistant Cancer Recurrence and Metastasis.

Authors:  Malachi A Blundon; Subhamoy Dasgupta
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

2.  Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging.

Authors:  Ziqi Zhu; Yoon-Mi Chung; Olga Sergeeva; Vladimir Kepe; Michael Berk; Jianneng Li; Hyun-Kyung Ko; Zhenfei Li; Marianne Petro; Frank P DiFilippo; Zhenghong Lee; Nima Sharifi
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

Review 3.  Emerging therapies to prevent skeletal morbidity in men with prostate cancer.

Authors:  Philip J Saylor; Richard J Lee; Matthew R Smith
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.

Authors:  Imtiaz A Siddiqui; Mohammad Asim; Bilal B Hafeez; Vaqar M Adhami; Rohinton S Tarapore; Hasan Mukhtar
Journal:  FASEB J       Date:  2010-12-21       Impact factor: 5.191

Review 5.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

7.  Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.

Authors:  Simone Filosto; David S Baston; Samuel Chung; Cathleen R Becker; Tzipora Goldkorn
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

8.  Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.

Authors:  Irwin H Gelman; Jennifer Peresie; Kevin H Eng; Barbara A Foster
Journal:  Mol Cancer Res       Date:  2014-07-22       Impact factor: 5.852

9.  Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.

Authors:  Yiwei Li; Zhiwei Wang; Dejuan Kong; Ran Li; Sanila H Sarkar; Fazlul H Sarkar
Journal:  J Biol Chem       Date:  2008-08-07       Impact factor: 5.157

10.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.

Authors:  T Koreckij; H Nguyen; L G Brown; E Y Yu; R L Vessella; E Corey
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.